Cargando…

Response to: Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations

Detalles Bibliográficos
Autores principales:	Citarella, Fabrizio, Russano, Marco, Perrone, Giuseppe, Vincenzi, Bruno, Tonini, Giuseppe, Santini, Daniele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169291/ https://www.ncbi.nlm.nih.gov/pubmed/33977646 http://dx.doi.org/10.1111/1759-7714.13997

Ejemplares similares

Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations
por: Masuda, Tomomi, et al.
Publicado: (2020)

The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations
por: Watanabe, Masahiro, et al.
Publicado: (2017)

Coronavirus Disease 2019 or Lung Cancer: What Should We Treat?
por: Russano, Marco, et al.
Publicado: (2020)

Cabozantinib and apixaban: an hitherto unreported interaction
por: Santini, Daniele, et al.
Publicado: (2019)

Facing SARS-CoV-2 outbreak in immunotherapy era
por: Citarella, Fabrizio, et al.
Publicado: (2020)

Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer
por: Tonini, Giuseppe, et al.
Publicado: (2013)

Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib
por: Manca, Paolo, et al.
Publicado: (2017)

Exploring the conformational dynamics and thermodynamics of EGFR S768I and G719X + S768I mutations in non-small cell lung cancer: An in silico approaches
por: Wang, Jun-Ling, et al.
Publicado: (2023)

Steroid-refractory immune related hepatitis may hide viral re-activation
por: Citarella, Fabrizio, et al.
Publicado: (2020)

Exceptional response to afatinib in a patient with persistent G719A EGFR-mutant NSCLC
por: Kulkarni, Amit A, et al.
Publicado: (2022)

Successful Resection of G719X-Positive Pleomorphic Carcinoma after Afatinib Treatment
por: Nakamura, Daisuke, et al.
Publicado: (2017)

Successful treatment of a patient with NSCLC carrying uncommon compound EGFR G719X and S768I mutations using osimertinib: A case report
por: Cai, Yangyang, et al.
Publicado: (2020)

Osimertinib Treatment Was Unsuccessful for Lung Adenocarcinoma with G719S, S768I, and T790M Mutations
por: Nasu, Shingo, et al.
Publicado: (2018)

Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan
por: Hsu, Ping-Chih, et al.
Publicado: (2023)

A rare case of double primary lung adenocarcinomas with uncommon complex EGFR G719X and S768I mutations and pleomorphic carcinoma
por: Morimoto, Toshiki, et al.
Publicado: (2023)

Effective Treatment With Afatinib of Lung Adenocarcinoma With Leptomeningeal Metastasis Harboring the Exon 18 p.G719A Mutation in the EGFR Gene Was Detected in Cerebrospinal Fluid: A Case Report
por: Ma, Chunhua, et al.
Publicado: (2020)

Prognostic and predictive factors in pancreatic cancer
por: Dell’Aquila, Emanuela, et al.
Publicado: (2020)

Durable response to afatinib rechallenge in a long‐term survivor of non‐small cell lung cancer harboring EGFR L858R and L747V mutations
por: Kanbe, Mio, et al.
Publicado: (2022)

Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples
por: Russano, Marco, et al.
Publicado: (2020)

Pazopanib and pancreatic toxicity: a case report
por: Russano, Marco, et al.
Publicado: (2015)

Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
por: Vincenzi, Bruno, et al.
Publicado: (2018)

Correction to: Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples
por: Russano, Marco, et al.
Publicado: (2020)

Gefitinib-induced hemorrhagic cystitis and inflammatory contracted bladder in a patient with advanced lung adenocarcinoma harboring compound epidermal growth factor receptor G719S and S768I missense mutations: a case report
por: Bai, Xueli, et al.
Publicado: (2022)

Unique characteristics of G719X and S768I compound double mutations of epidermal growth factor receptor (EGFR) gene in lung cancer of coal-producing areas of East Yunnan in Southwestern China
por: Wang, Jun-Ling, et al.
Publicado: (2022)

Large-Scale Profiling of Extracellular Vesicles Identified miR-625-5p as a Novel Biomarker of Immunotherapy Response in Advanced Non-Small-Cell Lung Cancer Patients
por: Pantano, Francesco, et al.
Publicado: (2022)

First-line targeted therapies in the treatment of metastatic colorectal cancer – role of cetuximab
por: Tonini, Giuseppe, et al.
Publicado: (2009)

Effectiveness of afatinib after ineffectiveness of gefitinib in an advanced lung adenocarcinoma patient with a single EGFR exon 20 S768I mutation: a case report
por: Duan, Hua, et al.
Publicado: (2018)

Successful treatment with afatinib following the failure of osimertinib rechallenge with osimertinib-induced interstitial lung disease: A case report
por: Sato, Yozo, et al.
Publicado: (2021)

Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
por: Lin, Ling, et al.
Publicado: (2020)

Successful erlotinib rechallenge in an EGFR‐mutant metastatic non‐small cell lung cancer patient with afatinib‐induced drug rash with eosinophilia and systemic symptoms: A case report
por: Lin, Chung‐Fu, et al.
Publicado: (2021)

Targeting bone metastases starting from the preneoplastic niche: home sweet home
por: Santini, Daniele, et al.
Publicado: (2011)

Case Report: The effective treatment of patients in advanced no-small cell lung cancer patients with EGFR G719X/S768I/L861Q and acquired MET amplification: A case series and literature review
por: Zhao, Yun, et al.
Publicado: (2023)

EGFR (p. G719A+L747V)/EML4-ALK Co-alterations in Lung Adenocarcinoma with Leptomeningeal Metastasis Responding to Afatinib Treatment: A Case Report
por: Lu, Zhiqin, et al.
Publicado: (2021)

A Novel Oncogenic Driver in a Lung Adenocarcinoma Patient Harboring an EGFR-KDD and Response to Afatinib
por: Chen, Dong, et al.
Publicado: (2020)

Effective treatment with icotinib in advanced lung adenocarcinoma harboring rare EGFR mutation G719A/L833V: A case report
por: Zhou, Bin, et al.
Publicado: (2022)

Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers
por: Russano, Marco, et al.
Publicado: (2023)

Tumor associated macrophages polarization dictates the efficacy of BCG instillation in non-muscle invasive urothelial bladder cancer
por: Suriano, Francesca, et al.
Publicado: (2013)

Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer
por: Santini, Daniele, et al.
Publicado: (2006)

Evidence-based guidelines: Improving AGREEment on consistence evaluation
por: Vincenzi, Bruno, et al.
Publicado: (2012)

A close relationship between HIF-1α expression and bone metastases in advanced NSCLC, a retrospective analysis
por: Pezzuto, Aldo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nposvi17hv5i6ci6g6cf0ali1e